中国临床药理学与治疗学2026，Vol.31Issue(3)：409-419,11.DOI:10.12092/j.issn.1009-2501.2026.03.013
酒精性肝病的发病机制和药物干预研究新进展
Research progress on pathogenesis and drug intervention of alco-holic liver disease
摘要
Abstract
Alcoholic liver disease(ALD)is a dis-ease of the liver that results from prolonged and heavy drinking,which is initially manifested as a fat-ty liver,and then develops into hepatitis,cirrhosis,and even hepatocellular carcinoma.The pathogene-sis of ALD is characterized by oxidative stress,im-mune inflammation,gut-hepatic axis,apoptosis,and autophagy induced by regulatory factors such as acetaldehyde dehydrogenase 2(ALDH2),nuclear factor-κB(NF-κB),and farnesol X receptor(FXR).This article takes regulatory factors as the entry point to summarize drugs such as the NF-κB in-hibitor ergacurone,the FXR agonist INT-787,and the PPARα agonist fenofibrate,and explores the current research status from broad treatment to targeted precision treatment.The aim is to gain a deeper understanding of the pathogenesis of ALD and provide a basic information for the prevention and control research of ALD and targeted drug in-tervention.关键词
酒精性肝病/发病机制/调控因子/药物治疗/靶向治疗Key words
alcoholic liver disease/pathogenesis/regulatory factor/pharmacotherapy/targeted ther-apy分类
医药卫生引用本文复制引用
张玉秀,贺博,张立君,冀乐,马壮,郑红星,祁珊珊..酒精性肝病的发病机制和药物干预研究新进展[J].中国临床药理学与治疗学,2026,31(3):409-419,11.基金项目
陕西省重点研发计划-重点产业创新链(群)项目(2024NC-ZD-CYL-04-27) （群）
陕西省秦创原产业聚集区"四链"融合项(2024CY-JJQ-32) （2024CY-JJQ-32）
陕西省秦创原科学家+工程师项目(2023KXJ-255) （2023KXJ-255）
陕西省教育厅地方专项(23JC020) （23JC020）
秦巴生物资源与生态环境省部共建国家重点实验室市校共建科研专项项目(SXC-2103) （SXC-2103）
陕西省科技厅农业一般项目(2024NC-YBXM-179) （2024NC-YBXM-179）
陕西省重点研发计划项目(2025NC-YBXM-149) （2025NC-YBXM-149）
农业农村部富硒产品开发与质量控制重点实验室/富硒食品开发国家地方联合工程实验室开放课题(Se-2024C06) （Se-2024C06）
